Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-02-03 (jdsupra.com)
Canadian trademark law 2024: a year in review | Smart & Biggar - JDSupra
In this article, we review a number of notable Canadian trademark cases from 2024 and highlight key developments in Canadian trademarks practice. On...
Read more
2025-01-17 (lequotidiendumedecin.fr)
Dr Éric Dumas (Federation of Memory Centers): “General practitioners can prepare for a key role in the treatment of early forms of Alzheimer’s” | The Doctor's Daily
DAILY DAY: Lecanémab – marketed under the name Leqembi (Eisai/Biogen) – could be available in France during 2025 and donanemab is currently being evaluated. What challenges arise for the general practitioner?
Read more
2024-11-18 (quechoisir.org)
The toxicities of marketing
Once again, the High Authority of Health (HAS) is wrongly accused of depriving French patients of access to therapeutic innovation. After immunotherapies or CAR-T treatments (gene therapies) in cancer, this time, it is for treatment of Charcot disease (amyotrophic lateral sclerosis) that she is in the dock.
Read more
2024-11-15 (blitz.bg)
The EMA is launching a cure for a dreaded scourge of our time
Leqembi, developed by the US multinational company Biogen and Japan's Eisai, is the trade name of an active substance called lecanemab
Read more
2024-11-15 (newmoney.gr)
European Medicines Agency: Approved new drug for Alzheimer's
"The EMA... has recommended that Leqembi (lecanemab) be given marketing authorization for the treatment of mild cognitive impairment or mild dementia due to Alzheimer's disease," the European Medicines Agency said
Read more
2024-11-15 (mikrometoxos.gr)
Conditional trial of anti-Alzheimer's drug approved by the European Medicines Agency
Conditional trial of anti-Alzheimer's drug approved by European Medicines Agency - Magazino
Read more
2024-09-25 (elpais.com)
A scientific rebellion to get Europe to approve a controversial Alzheimer’s drug
The new monoclonal antibody lecanemab has been greenlighted by the US and other countries, but the European Medicines Agency considers that the benefits do not outweigh the risks
Read more
2024-09-23 (heraldtribune.com)
Two landmark Alzheimer's drugs linked to research by Sarasota Roskamp Institute founders
Two new drug treatments prove effective in forestalling the start of early onset Alzheimer's; Roskamp will eventually offer infusion treatments
Read more
2024-08-07 (sundhedspolitisktidsskrift.dk)
Big disappointment: EMA puts the brakes on new Alzheimer's drug in Europe
Sundhedspolitik Tidsskrift gives you news about health policy, new treatments, health economics and debate about health problems and policy
Read more
2023-08-17 (bbrfoundation.org)
Rapid-Acting Pill to Treat Postpartum Depression is Approved
On August 4th, the U.S. Food and Drug Administration (FDA) approved zuranolone, the first oral medication designed to treat postpartum depression (PPD) in adults. The drug, which is rapid-acting, was developed by Sage Therapeutics and Biogen, and will be marketed under the name Zurzuvae.
Read more
2023-07-17 (arstechnica.com)
Eli Lilly drug shown to slow Alzheimer’s progression
Dementia experts hail "watershed moment" after trial results for donanemab antibody treatment.
Read more
2023-07-17 (ft.com)
FirstFT: ‘Watershed moment’ as Eli Lilly drug shown to slow Alzheimer’s progression
Also in today’s newsletter, Russia pulls out of Black Sea grain deal and the mysterious absence of China’s foreign minister
Read more